The hosts challenge the conventional accounting of AI training runs as R&D (OpEx). They propose viewing a trained model as a capital asset (CapEx) with a multi-year lifespan, capable of generating revenue like a profitable mini-company. This re-framing is critical for valuation, as a company could have a long tail of profitable legacy models serving niche user bases.

Traditional accounting metrics misrepresent the financial health of AI companies. Their largest expenditure, acquiring compute power, should be viewed as an investment in a valuable, appreciating asset, not as a typical operating expense. This reframes the narrative around their massive cash burn.

The long-held belief that a complex codebase provides a durable competitive advantage is becoming obsolete due to AI. As software becomes easier to replicate, defensibility shifts away from the technology itself and back toward classic business moats like network effects, brand reputation, and deep industry integration.

Established metrics for evaluating software (high gross margins, capital-light) are obsolete in the AI paradigm. Top AI companies often exhibit opposite traits, like low margins due to inference costs, signaling the "death of spreadsheet investing."

Traditional valuation multiples are increasingly misleading because GAAP rules expense intangible investments (R&D, brand building) rather than capitalizing them. For a company like Microsoft, properly capitalizing these investments can drop its P/E ratio from 35 to 30, revealing a more attractive valuation.

The true differentiator for top-tier companies isn't their ability to attract investors, but how efficiently they convert invested capital into high-margin, high-growth revenue. This 'capital efficiency' is the key metric Karmel Capital uses to identify elite performers among a universe of well-funded businesses.

Adjusting financial statements to capitalize R&D provides a more accurate book value for tech firms. However, this input-based approach is limited, as the value of an intangible asset, like a successful drug patent, is non-linear and disconnected from its historical cost.

The CEO of Judges Scientific uses Return on Total Invested Capital (ROTIC) instead of the more common ROCE. He argues ROCE is an "accounting fiction" because amortization shrinks the capital base over time, artificially inflating returns. ROTIC provides a more honest measure based on the actual capital invested.

Companies investing heavily in intangibles like R&D often see a temporary drop in earnings per share (EPS). This spending, however, builds long-term competitive advantages and moats, leading to substantial EPS growth over a multi-year horizon.